9a6cadb47b073bf4.T14NxINCG4wxdgvtxJOwVUQR39mfLzAOxNNgG7R4A3s.AAp_9e0HSdZQRFKbgKCCLSl0qL7MX0RbpYcCaNc_O0sCK36b9RBP1mYHeA
11-16 UBS raises price target for Genmab to DKK 4,900 (3,100), reiterates buy FW
11-12 Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons GL
11-11 Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons GL
11-11 Genmab A/S : has published its Articles of Association PU
11-10 Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons GL
11-10 Capital Increase in Genmab as a Result of Employee Warrant Exercise GL
11-09 Genmab rises 4 percent after J&J's FDA approval for cancer drug FW
11-06 Genmab: Strong profit beat but guidance unchanged; time to book profits Alphavalue
11-06 Goldman Sachs raises price target for Genmab to DKK4,500 (4,450), reiterates buy - BN FW
11-05 Genmab A/S, Nine Months 2026 Earnings Call, Nov 05, 2026
11-05 Genmab A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 CI
11-05 Genmab A/S Maintains Earnings Guidance for the Year 2026 CI
11-05 Genmab A/S : Interim Report for the First Nine Months of 2026 PU
11-05 Genmab beats expectations for operating profit, reiterates outlook FW
11-05 Genmab Announces Financial Results for the Nine Months of 2026 GL
11-04 Genmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting BU
11-04 Genmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting GL
11-04 Genmab A/S Presents Results From Comprehensive Epcoritamab Development Program At The 2026 American Society Of Hematology Annual Meeting CI
11-02 Bank of America raises Genmab's price target to DKK 4,400 (4,200), reiterates Buy FW
10-30 AlphaValue/Baader Europe Upgrades Genmab to Reduce MT
10-29 Deutsche Bank raises price target for Genmab to DKK 4,000 (3,500), reiterates buy - BN FW
10-29 AlphaValue/Baader Europe Downgrades Genmab to Sell MT
10-29 Goldman Sachs raises its price target for Genmab to 4,450 Danish kroner (2,400), reiterates buy FW
10-29 Genmab: Positive developments priced in; time to take profits Alphavalue
10-29 SEB raises price target for Genmab to DKK 4,600 (3,175), reiterates buy FW

Become a member to access more news

New member
No results match your criteria